MilliporeSigma

BioReliance® Contract Testing Services

No. 1 for Innovation


Our BioReliance® biosafety testing and analytical development services deliver risk-mitigating solutions with technical and regulatory expertise. We have been shaping the biosafety testing industry for more than 75 years. We help ensure the safety of the world’s biologics with innovations such as:

  • Supported and tested the first polio vaccines
  • Tested lunar samples from NASA
  • Began biosafety testing for the first licensed monoclonal antibody product in 1983

No. 1 for clients: New Paradigms in Biosafety Testing that put Our Clients Ahead

The upcoming revision of ICHQ5A will include the use of new technologies and viral clearance strategies to also examine cell, gene therapies and newer vaccine paradigms such as virus like particles, subunit proteins, and viral vectors.

Helping to navigate the regulatory landscape: ICH Q5A(r2)

The recent revision of ICH Q5A encourages the use of new technologies and viral clearance strategies to ensure viral safety of biologics. Viral safety assurance of gene therapies, virus-like particles, and viral vector products is now required.

A comprehensive risk mitigation strategy using multiple orthogonal measures is a regulatory requirement. ICH Q5A, the globally-harmonized guideline outlines the expectations. It has recently been revised to address scientific advancements including novel therapeutic modalities, new manufacturing paradigms, updates in viral clearance applications, and advanced detection technologies.

Regulations are changing to be more accepting / even encouraging the adoption of new technologies.

Biologics such as monoclonal antibodies and gene therapies are a significant portion of the therapeutics market. ICH Q5A outlines regulatory expectations for viral risk mitigation in biologics manufacturing. The revision encourages the use of Next Generation Sequencing (NGS) and PCR-based technologies.

ICH Q5A

Accelerating Development with the Award-winning Blazar® Platform

Accelerating Development with the Award-winning Blazar® Platform

In today’s environment speeding biologics to market is more important than ever. The Blazar® platform not only helps accelerate CLC but allows clients to meet corporate objectives to reduce in vivo testing. Innovative molecular methods enable mAbs manufacturers to deliver critical therapeutic agents to patients faster. The Blazar® CHO AOF virus panel is a powerful tool to accelerate bulk harvest testing with the potential to replace slower culture-based in vitro virus detection methods.

The platform is a novel degenerate PCR assay for the detection of a broad range of adventitious agents. With the advantages of sensitivity, accuracy, and faster results, combined with the ability to detect a very broad range of viruses, this platform is well suited to cell line characterization and bulk-harvest lot release testing.

We are committed to accelerating testing and helping the industry reduce the use of animal models. We have developed a rodent virus panel for the Blazar® platform. This rodent virus panel provides a suitable alternative to the current in vivo MAP/HAP/RAP test that eliminates the need for animals.

Blazar® Platform

Accelerating Development with the Award-winning Blazar® Platform

Speed. Sustainability. Safety. Pioneering NGS applications

Revolutionizing the development and analysis of biologic therapeutics, NGS allows you to meet the challenge of rapidly characterizing your products, while identifying known and unknown agents with pinpoint precision and accuracy.

Our suite of NGS services is based on complementary technology platforms that rapidly generate deep sequencing datasets for comprehensive data analysis, backed by biosafety experts who deliver intelligent results tailored to your unique testing needs.

As a leading service provider, we have pioneered the use of NGS to expand our portfolio of GMP testing services, including the use of NGS to detect and identify adventitious agent sequence signatures that may be present in a test sample. This application of NGS affords the biopharmaceutical industry with a valuable tool to mitigate the risk of viral contamination in a variety of samples from production starting materials to bulk harvests and final product.

The ability of NGS-based methods for agnostic broad range detection makes it a suitable option to augment or replace current virus testing methodology.

Regulatory authorities are receptive to the use of novel technologies as alternatives to established virus detection methods, as long as the alternative testing strategies are properly validated, shown to be fit for purpose for the sample being tested, and are comparable or better than existing assays.

Next Generation Sequencing


1947
Produced a single product, serum ultra filtrate for the newly-emerging tissue culture field.
1951
First commercial supplier of cell cultures and reagents.
1955
First contract R&D program with U.S. Govt and National Foundation for Infantile Paralysis to support development and production of the first polio vaccines.
1956–1960
Started producing viral diagnostic products.
1960s
Collaboration with the NIH, developed new technologies for viral disease diagnoses of laboratory animals. Developed the Mouse Antibody Production (MAP) test.
1969
Supported NASA in development of safety testing protocols for lunar samples brought back from the moon’s surface.
1978
First to license and market an ELISA diagnostic test for detection of cytomegalvovirus (CMV).
1981
Together with Genentech, established the original biosafety testing program for what becomes the first licensed therapeutic derived from mammalian cells (Activase).
1983
Began biosafety testing for what becomes the first licensed therapeutic monoclonal antibody product (Ortho Pharmaceutical’s Orthomune OKT-3).
1988
Tested the first genetically engineered microbial pesticide to be approved by the EPA for field trials (Bacillus thunringiensis).
1989
First major R&D collaboration to develop and validate a transgenic mouse for safety testing of chemical products (Strategene’s Big Blue®).
1990
Developed first protocols and evaluate the first gene therapy products allowed into human clinical trials by the FDA.
1994
Conducted safety testing for the first liver transplanted from a baboon to a human.
1995
Performed analytical testing of pharmaceuticals, focusing on macromolecules and providing characterization services using analytical techniques.
2007
Introduces iNet client portal to facilitate sample submission and client access to study results.
2020
Launch of award-winning Blazar® platform.

Services

Product Characterization & Biosafety Testing

Biologics Testing, Product Characterization

We deliver brilliant biosafety testing experiences through the entire drug lifecycle. Our comprehensive product characterization program reveals the true identity of your molecule through every phase of development, ensuring your biotherapy’s safety, purity and potency.

Explore our pharma and biopharma testing services in more depth:

Biopharma Testing Services


The Sharpest Perspective in Life Science

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?